Etodolac in Postsurgical Pain: Double-Blind, Dose-Ranging Efficacy Study with Aspirin and Placebo

Publisher Website
Google Scholar
Abstract
Etodolac (AY-24, 236) is a new non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic activity(1). In rat studies of analgesic and antipyretic activity, the compound was respectively 5 and 10 times more potent than aspirin(2). It is less irritant to the rat gastric mucosa than indomethacin, ibuprofen, naproxen, sulindac and tolmetin(3). Given orally in twice daily doses of 300 mg for a period of 7 days, Etodolac produced no greater fecal blood loss than placebo and significantly less than aspirin 650 mg given four times a day over the same period(4). Keywords Pain Relief Pain Intensity Significant Linear Trend Postsurgical Pain Antipyretic Activity These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.